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ABSTRACT 
The Joint Commission in a joint effort with the Centers of Medicare and Medicaid 
Services (CMS) has established certain “core measures” by which hospital performance is 
measured.  One of these is the measure for patients with ST-elevation myocardial infarction 
(STEMI) recommending percutaneous coronary intervention within 90 minutes of presentation 
to the Emergency Department in institutions that are able to provide this service.  This 
recommendation does not take into account the long-term use of clopidogrel that is 
recommended by the American College of Cardiology and American Heart Association for 
patients that are treated with coronary stents.   
The purpose of this study was to evaluate outcomes of providing a short course of 
clopidogrel versus a prescription alone for clopidogrel to uninsured patients experiencing STEMI 
who were treated with a bare metal stent. 
After conducting a cost-benefit analysis, a policy was approved that provided uninsured 
STEMI patients with clopidogrel at discharge rather than a prescription.  A social worker 
evaluated patients to determine if they met criteria and arranged for medication delivery to the 
patient’s bedside.  A retrospective chart review for all patients who presented to the Emergency 
Department during two different time frames (before and after policy implementation) was 
conducted to evaluate if providing clopidogrel decreased readmissions.  Data were collected on 
over a 15-month period of time before and after the clopidogrel policy implementation to allow 
for evaluation of 90-day readmissions with repeat STEMI.  Data were analyzed using chi-square 
cross tabulation and T-test for independent samples.   
A total of 201 charts were reviewed:  100 from the pre-intervention group and 101 from 
the post-intervention group.  Demographic characteristics of age, gender and insurance status 
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were not statistically different between groups.  The mean age for the control group was 59.1 (+ 
13.8) years and 58.9 (+ 13.6) years for the intervention group.  Twenty percent of the patients 
were uninsured.  Five uninsured patients were readmitted with STEMI prior to the intervention 
compared to two patients in the intervention group (p = .191).  The admissions for the pre-
intervention patients occurred in the first 30 days after discharge compared to 31-60 days in the 
post-intervention group.  All of the patients who were readmitted were assessed to be 
noncompliant with treatment.  Additionally, a transition to increased use of bare metal stents in 
STEMI patients from 23.1% pre-intervention to 67.4% post-intervention was noted (p < .001).   
Although no differences were found in readmission rates, fewer readmissions for STEMI 
were noted after the intervention.  The small number of patients who were readmitted with 
STEMI likely accounted for this finding, and additional monitoring of readmission rates is 
warranted.  Despite provision of the clopidogrel, adherence remains an issue and needs to be 
addressed.  During the intervention, physicians were encouraged to consider the financial and 
social resources of individual STEMI patients presenting to the Emergency Department to help 
identify patients that would be less likely to adhere to antiplatelet therapy.  In those believed to 
be at high risk for non-adherence, primarily due to inability to purchase the relatively expensive 
medication clopidogrel, many physicians chose to insert bare metal stents rather than drug-
eluting stents to take advantage of the shorter course of clopidogrel required post procedure.  
Provision of a 30-day course of clopidogrel and aspirin was a major part of this effort to decrease 
recurrent myocardial infarction in this at-risk population.  A few patients eligible for the 
clopidogrel were not provided the medication if they were admitted to a nursing unit where staff 
members were not familiar with the policy; revisions to the policy to ensure medication is 
provided to all eligible patients will be made.  Providing clopidogrel to patients who experience 
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STEMI may improve adherence and thereby decrease readmissions as a result of repeat STEMI 
due to subacute thrombus formation.  Patients who experience STEMI continue to be vulnerable 
after STEMI.  Programs that provide medication to patients should be expanded within this 
facility and to other hospital systems to encompass all patients who are treated for STEMI.  
Multi-disciplinary collaboration is necessary in developing and implementing a program that will 
address care for this. 
 
 
 
 
 
  
 vi 
 
 
 
 
 
 
This paper is dedicated to my parents who fill me with their love and strength. 
 vii 
ACKNOWLEDGMENTS 
 This project was developed as a result of the passion for excellent patient care across the 
continuum exhibited by one physician.  Robert P. Dalton, MD experienced a tragic outcome for 
one of his patients as a result of a breakdown in transition from inpatient to outpatient care.  
Based on this one patient he challenged me to find a solution and I hope that with this project I 
have met his expectations.   
      I also want to extend appreciation to Mary Lou Sole, PhD who was my advisor 
throughout this program.  Dr. Sole never let me give up and for that I am always grateful. 
      Finally, I have to thank my Imagine South Lake Charter School family and especially 
Mrs. Christine Watson.  They cared for my children and supported me at every turn, always 
encouraging me to continue and be successful.  This project would never have been completed 
without the faculty and leadership at this wonderful charter school in Lake County, Florida. 
 viii 
TABLE OF CONTENTS 
LIST OF FIGURES ........................................................................................................................ x 
LIST OF TABLES ......................................................................................................................... xi 
CHAPTER ONE: INTRODUCTION ............................................................................................. 1 
Background ................................................................................................................................. 2 
Problem ....................................................................................................................................... 3 
Objective/Aim ............................................................................................................................. 5 
Research Questions ..................................................................................................................... 6 
Definitions................................................................................................................................... 6 
Assumptions ................................................................................................................................ 7 
Study Importance ........................................................................................................................ 7 
CHAPTER TWO: LITERATURE REVIEW ................................................................................. 8 
Adherence as a Concept ............................................................................................................ 10 
Barriers to Adherence ............................................................................................................... 11 
Barriers to Adherence in the Cardiovascular Patient ................................................................ 12 
Summary ................................................................................................................................... 20 
CHAPTER THREE: METHODS ................................................................................................. 21 
Implementation of Project......................................................................................................... 21 
Design ....................................................................................................................................... 22 
Variables ................................................................................................................................... 23 
Setting/Subjects/Sampling ........................................................................................................ 23 
Human Subjects ........................................................................................................................ 24 
Instruments/Data Collection Tool ............................................................................................. 25 
 ix 
Procedures ................................................................................................................................. 26 
Data Collection Tool ................................................................................................................. 27 
Data Analysis ............................................................................................................................ 27 
Limitations ................................................................................................................................ 28 
Summary ................................................................................................................................... 28 
CHAPTER FOUR: RESULTS ..................................................................................................... 29 
Demographics ........................................................................................................................... 29 
Readmissions ............................................................................................................................ 31 
Additional Findings .................................................................................................................. 32 
CHAPTER FIVE: CONCLUSION............................................................................................... 34 
Discussion ................................................................................................................................. 34 
Additional Findings .................................................................................................................. 37 
Limitations ................................................................................................................................ 38 
Implications for Nursing Practice ............................................................................................. 39 
Recommendations for Further Research ................................................................................... 40 
Conclusions ............................................................................................................................... 41 
APPENDIX A: PLAVIX PROVISION FOR INDIGENT CODE STEMI STENT RECIPIENTS
........................................................................................................................................... 43 
APPENDIX B: DATA COLLECTION TOOL ............................................................................ 46 
APPENDIX C: UCF IRB ............................................................................................................. 48 
APPENDIX D: ORMC IRB ......................................................................................................... 50 
LIST OF REFERENCES .............................................................................................................. 52 
 x 
LIST OF FIGURES 
Figure 1: Literature Search Results................................................................................................. 9 
 
 xi 
LIST OF TABLES 
Table 1: Project Definitions ............................................................................................................ 6 
Table 2: Summary Table ............................................................................................................... 14 
Table 3: Demographics ................................................................................................................. 30 
Table 4: Readmission of Patients (n = 43) .................................................................................... 32 
Table 5:  Medication Adherence by MD Documentation ............................................................. 33 
 
 
 1 
CHAPTER ONE: INTRODUCTION 
In February 2006, a 581-bed tertiary care center in Central Florida initiated a Code 
STEMI process to provide timely interventional care to patients presenting to the Emergency 
Department (ED) with ST- segment elevation myocardial infarction (STEMI).  In July 2006, 
after approximately 50 patients had been treated using the Code STEMI process, a 55-year old, 
female patient presented to the ED with signs and symptoms consistent with STEMI. She was 
treated in a very timely manner using the same process.  In this particular case, the physician had 
determined that there was a potential for medication non-adherence and therefore treated her 
with a bare metal stent (BMS).  The patient had a successful outcome and was discharged home 
after 2 days.  Prior to discharge the patient was educated regarding the importance of medication 
adherence and she reassured the physician and nurses that she understood and that she would 
take her follow-up medications.   
As was the hospital policy at the time, the patient was given a 7-day supply of 
clopidogrel through the Social Work department.  She was also referred to the County Medical 
Clinic (CMC) for follow up.  It was at this point that she ‘fell through the cracks’.  The earliest 
that the patient was able to schedule an appointment with the CMC was two weeks after the date 
of discharge (actually a timely appointment).  She took her medication as she was instructed, but 
ran out of medication one week prior to her appointment and was unable to afford a refill.  Once 
she was seen by the CMC, she received more clopidogrel and began taking her medication as 
prescribed.  Unfortunately, in the one week that she did not take clopidogrel, she developed 
subacute thrombosis in the previously placed stent and she returned to the ED with an more 
serious STEMI the following evening.  While she was again treated in a very timely manner, the 
second STEMI resulted in complete embarrassment of her cardiac function and she required a 
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prolonged stay in the coronary care unit (CCU). While in the CCU, she required treatment with 
balloon counterpulsation and nearly died.  The second STEMI resulted in unnecessary suffering 
for the patient and likely shortened her life. 
This patient event was the impetus for designing a project based on the available 
evidence for treating STEMI patients. The intent of this project is to help patients with 
clopidogrel adherence and decrease the occurrence of subacute thrombosis. 
Background 
Coronary heart disease (CHD) is the killer of more Americans than any other single 
disease.  CHD includes acute myocardial infarction (AMI), acute coronary syndromes (ACS), 
and angina pectoris.  The American Heart Association (AHA) estimates that 565,000 new AMI’s 
occur annually while there are about 300,000 occurrences of repeat AMI each year. In 2004, 
157,559 people in the United States died as a result of an AMI (American Heart Association, 
2007).  AMI is identified using electrocardiography (ECG) and cardiac enzymes (CPK-MB and 
troponins).  STEMI is one type of AMI and is easily and quickly identified using ECG.  This 
tends to be the more immediately lethal form of AMI and resources to expedite care of these 
patients presenting to healthcare facilities has been the focus of a world-wide initiative in recent 
years.  
A large volume of data shows early recognition and treatment of patients with STEMI 
results in improved outcomes for these patients (Faxon, 2007). Options for treating patients with 
AMI that present to the hospital typically have included percutaneous coronary intervention 
(PCI), which includes balloon angioplasty and/or stent deployment, atherectomy, and 
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thrombectomy; or the use of fibrinolytics.  Our facility’s current practice is to facilitate emergent 
coronary  thrombectomy and stent placement in most cases. 
The Joint Commission, in conjunction with the Centers for Medicare and Medicaid 
Services (CMS), developed a set of measurable outcomes for certain disease states that each 
accredited hospital in the United States (US) must measure and report.  These diseases were 
chosen based on prevalence and literature support that quality of care and outcomes could be 
improved with consistent delivery of treatment.  AMI is included in these measures (The Joint 
Commission, Centers for Medicare and Medicaid Services, 2006).  
The AMI core measure is made up of nine indicators. The two indicators that affect early 
intervention of STEMI are AMI-7 and AMI 7a, median time to fibrinolysis, and fibrinolytic 
therapy received within 30 minutes of arrival to hospital; and AMI-8 and AMI 8a, median time 
to primary PCI and primary PCI received within 90 minutes of arrival to hospital. Because the 
use of fibrinolytics has decreased due to the ease of access to interventional cardiac 
catheterization labs and data that shows PCI received within 90 minutes for patients presenting to 
the ED where primary PCI is performed or within 120 minutes for patients presenting to an ED 
of a facility that does not provide PCI and requires transfer results in decreased mortality and 
morbidity, this discussion focuses on indicators AMI 8 and AMI 8a.   
Problem 
Prior to the implementation of the The Joint Commission / CMS AMI indicators, a 
patient was evaluated for PCI versus fibrinolytics based on financial status and ability and/or 
willingness to be compliant with long-term medications. As treatment has trended towards early 
PCI, it is important to recognize that when PCI involves stent deployment (which is common), 
 4 
continued medical treatment with clopidogrel is necessary to decrease the risk of subacute 
thrombosis.  
Subacute thrombosis is defined as partial or total stent occlusion in the initial stent as 
documented by angiography (Iakovou, 2005).  Antiplatelet agents (i.e. clopidogrel and aspirin) 
decrease the risk of subacute thrombosis.  The American College of Cardiology/American Heart 
Association (ACC/AHA) recommend varying lengths of antiplatelet therapy based on the type of 
stent that is placed.  ACC/AHA recommends a minimum of 12 months of clopidogrel for 
patients who receive a drug-eluting stent (DES) and are not at high risk for bleeding.  In patients 
that receive a bare metal stent (BMS), ACC/AHA recommends a minimum of one month of 
clopidogrel, but also notes that it would be ideal to continue clopidogrel for 12 months (Antman 
et al., 2008).  Unfortunately, the cost for clopidogrel ranges from $5.60 to $6.10 per tablet at 
local pharmacies and no generic preparation available.  Uninsured or underinsured patiens 
without financial resources sufficient to purchase these medications easily are at particularly high 
risk for non-adherence. 
In an effort to meet the CMS AMI indicators, a Central Florida tertiary care center 
implemented a Code STEMI process in February 2006.  This process focuses on early 
recognition by the ED and rapid activation of and transport to the cardiac catheterization lab. 
This ensures that patients having a STEMI are receiving the same quality care on an inpatient 
basis regardless of financial status and ability to pay. While the intent of the core measures is to 
provide the best care to all STEMI patients presenting to the hospital, they do not take into 
consideration the ability of the patient to adhere to necessary follow up care.  The component of 
medication adherence post procedurally has been neglected in considering the care of these 
patients. 
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Once the STEMI program was initiated at the facility, the number of Code STEMI’s 
treated during the first year was obtained and noted to be 97 cases, an average of 8.1 cases per 
month.  Of these STEMI’s, 17 were identified as patients who were either uninsured or who 
might have some difficulty paying for the clopidogrel.   
Four of the 17 patients that underwent PCI during this period of time were readmitted to 
the facility through the ED with subacute thrombosis in the recently implanted stent.  All four of 
these patients returned within 1 months of discharge.  In all four cases the physicians 
documented non-adherence with regards to clopidogrel.  In other words, 23.5% of uninsured 
patients were readmitted with subacute thrombosis as a result of being non-adherent to their anti-
platelet regimen. 
Objective/Aim 
The main objective of this project is to evaluate outcomes of providing clopidogrel 
(actual medication rather than a prescription that the patient will have to fill) to all uninsured 
patients presenting to the tertiary care center with STEMI who receive BMS or DES as their 
method of treatment. The assumption is that if the patient is provided with this very costly 
medication, he/she will be more likely to adhere to the prescribed medication regimen. 
Comparing three-month readmission rates for patients with STEMI will assess medication 
adherence. The time period reviewed for initial presentation with STEMI will be from February 
2009 to February 2010.  Readmissions (repeat STEMI) will be reviewed for the time period 
beginning February 2009 and ending May 2010 to ensure that 3-month readmission data are 
captured. 
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Research Questions 
1. Is there a difference in readmission rates between uninsured STEMI patients who receive 
medication, actual “drug-in-hand”, and those who receive a prescription to fill? 
2. Are uninsured patients who receive “drug-in-hand” less likely to be readmitted than 
insured patients who receive a prescription to fill? 
Definitions 
For this project, terms are defined as follows: 
 
Table 1: Project Definitions 
Term Conceptual Definition Operational Definition 
Subacute thrombosis A partial or total stent 
occlusion in the initial stent 
as documented by 
angiography (Iakovou, 
2005). 
Documentation in 
catheterization report by 
interventional cardiologist. 
Adherence Taking medications as 
prescribed. 
No readmission within 3 
months of initial AMI 
assumes adherence 
Medication provision Patient will have “drug in 
hand” (clopidogrel and 
aspirin only) prior to 
discharge. 
Documentation by the 
Social Work Department 
that medication was 
provided to patient prior to 
discharge. 
True uninsured Patients for whom no 
evidence of insurance 
coverage can be found. 
Business office verification. 
Prescription Paper prescription for 
clopidogrel that is given to 
the patient. 
Patient discharge 
assessment form, absent 
documentation of 
medication provision. 
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Assumptions 
For the purposes of this project, the following assumptions are made: 
1. Patients will take medication if it is provided to them 
2. Medication adherence is assumed when a patient is not readmitted with repeat STEMI 
within the study period. 
3. Uninsured patients find it more difficult to afford medications. 
Study Importance 
The importance of this project revolves around patient outcomes.  Patients that have a 
STEMI are in a position to receive the best interventional care available.  Unfortunately, this care 
does not always ensure positive long-term outcomes.  This is, in part, due to the cost of 
medication that is required to help ensure stent patency. If providing medication to patients 
promotes medication adherence, a catastrophic cost to the patient, in addition to the burden on 
the health care system and society, may be avoided. 
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CHAPTER TWO: LITERATURE REVIEW 
An integrative review of the literature was conducted to evaluate the concept of 
adherence, specifically medication adherence. To begin the integrative review, the CINAHL and 
PubMed databases were searched.  Key words that were searched were adherence, medication, 
clopidogrel and cardiac.  The search of the electronic database was limited to English articles 
from 2004 to 2010.  The year limitation was chosen to obtain the most recent research pertaining 
to medication adherence.  Using the key words adherence and medication, 2,364 articles were 
returned.  Combining medication with adherence or compliance returned 592 articles. When the 
terms cardiac and clopidogrel were added, 51 articles were returned.  Of these 51 articles, 5 
articles were an actual analysis of the concept of adherence.  An additional 9 articles that 
pertained directly to medication adherence in patients with diagnosed cardiac disease, with one 
article specifically discussing adherence to clopidogrel, were included in the review (Figure 1).  
Medication compliance was used in the search because it is frequently used interchangeably with 
adherence. Antecedents that were identified in the search were compliance, concordance, and 
non-adherence. 
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Figure 1: Literature Search Results 
 
The World Health Organization (WHO) defines adherence as “the extent to which a 
person's behavior – taking medication, following a diet, and/or executing lifestyle changes, 
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corresponds with agreed recommendations from a health-care provider.”  Terms that have been 
recognized as interchangeable with adherence include compliance and concordance (Rolley, et 
al, 2008). 
Compliance is a term that is not frequently used due to the negative connotation that it 
carries (Shay, 2007, Bissonnette, 2008).  The term compliance indicates an unequal relationship 
between provider and patient due to the paternal undertones it carries (Bissonnette, 2008).  
Compliance also refers to obedience, which detracts from a collaborative relationship with a 
provider (Bissonnette, 2008). Different ways of viewing the term compliance within healthcare 
have been identified and it is the way that it is viewed that determines the connotation.  The three 
ways of viewing compliance are evaluative, rationalization, and acceptance.  When compliance 
is viewed in an evaluative manner, patients may be seen as difficult if they are not compliant in 
their therapies (Shay, 2007).   
Adherence as a Concept 
The WHO definition of adherence indicates a more collaborative relationship between 
patient and provider.  Another very common definition of adherence is how well the patient 
follows a prescribed treatment regimen (Haynes, et al, 2005). Adherence is also considered to be 
non-judgmental and is the preferred term when discussing patients’ health behaviors in relation 
to prescribed medication therapies (Julius, et al, 2009).  Poor adherence to prescribed medical 
therapies increases mortality and morbidity in certain diagnoses (Wu, et al, 2008). 
From adherence, there has been a gradual movement towards the term concordance, 
which suggests a more participative relationship between patient and provider. Concordance also 
suggests that a negotiation between patient and provider has led to an agreement suitable to both 
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parties (Bissonnette, 2008, Lehane & McCarthy, 2009). However, there is currently limited 
research related to concordance as an individual concept (Bissonnette, 2008).  There is an 
abundance of literature addressing concordance as a synonym for adherence. 
     Non-adherence is a concept that is used interchangeably with lack of, or poor adherence.  
Non-adherence is recognized as a serious health issue. Recommendations have been made to 
elevate the issue of non-adherence to a critical health care issue.  Non-adherence leads to 
increases in hospitalization, mortality and morbidity (Lehane & McCarthy, 2009, Wu, et al, 
2008). 
Barriers to Adherence 
Factors affecting medication adherence fall into four areas:  patient-related, 
psychological, medication-related, and social/environmental.  Patient related factors include age, 
gender, marital status and ethnicity.  Of more interest are the psychological risk factors, which 
are denial of illness and negative attitudes about medications (Julius, et al, 2009).  Negative 
attitudes about medications are attributed to patient concerns about necessity and safety of 
prescribed medications (Aikens & Piette, 2009).  
Medication-related factors that contribute to non-adherence are side effects and dosing 
schedules.  More complex dosing schedules are associated with decreased adherence (Julius, et 
al, 2009). 
The other factors that influence medication adherence are social and environmental 
factors.  A collaborative or therapeutic relationship with a provider improves medication 
adherence (Julius, et al, 2009). Socioeconomic status also contributes to adherence as 
demonstrated by decreased adherence to lipid lowering agents when co-pays are increased 
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(Doshi, et al, 2009).  A predictive study by Choudry, et al (2007) suggested that post AMI 
patients that had no out-of-pocket costs for medications after hospitalizations would be more 
adherent to medication regimens.  Through medication adherence, a resultant cost savings was 
predicted based on decreased rehospitalizations.  Cost was also cited as a reason for not filling 
prescriptions for clopidogrel by patients who had received a coronary stent.  This is an example 
of non-adherence that can lead to rehospitalization as discontinuation of clopidogrel by patients 
with stent placement puts them at risk for in-stent thrombus formation (Jackevicius, et al, 2007). 
Barriers to Adherence in the Cardiovascular Patient 
Medication adherence in cardiovascular disorders is well documented.  Heart failure is an 
area where medication non-adherence has been shown to increase the risk of mortality and 
morbidity as well as increase health costs (Wu, et al, 2008).  Medication adherence is also linked 
with self-efficacy.  Schoenthaler, et al (2009) showed that self-efficacy mediates the relationship 
between depression and adherence.  It was noted that depressive symptoms led to medication 
non-adherence.  Depression in patients experiencing acute myocardial infarction (AMI) is 
prevalent as seen by the number of prescriptions for antidepressants prescribed at discharge for 
these patients (Jackevicius, et al, 2007). 
Another area that contributes to decreased adherence in patients diagnosed with acute 
coronary syndrome (ACS) was partner stress defined as stress or conflict within a relationship 
(Molloy, et al, 2008).  In this study, partner stress within six months prior to onset of ACS 
predicted medication non-adherence. 
Discharge medication counseling by pharmacists has been shown to improve medication 
adherence and understanding.  Interventions that occur at the time of an acute event have been 
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shown to increase adherence to prescribed treatment therapies; therefore, discharge medication 
counseling has the potential to improve long-term adherence. However, discussion of discharge 
medication counseling has been inconsistent (Jackevicius, et al, 2007). 
The most recent article addressing adherence in the cardiac patient was specific to 
clopidogrel adherence.  The focus of this article was prescription filling and delays associated 
with filling.  The authors identified factors associated with delays to include advanced age, prior 
AMI, other comorbidities such as diabetes or renal failure, and in-hospital bleeding (Jackevicius, 
et al, 2010).  Cost as a barrier was not addressed.  In this article the authors emphasized the 
importance of transition care in patients that have DES implanted (see Table 2). 
 
 
 14 
Table 2: Summary Table 
Authors/ 
Year/ 
Country 
Discipline Methods Sample/Setting Findings 
Aikens, J.E. & 
Piette, J.D.  
(2009) 
Psychosocial Face to face interviews, Bayer 
2000 analyzer for HgbA1C, Omron 
automatic BP monitor with 
appropriately sized cuff for BP 
measurement 
806 type II diabetics on 
antihyperglycemic and 
antihypertensive 
medications 
Up to one half of patients 
underused their medications as a 
result of low health literacy, cost 
of medications, perceived need 
for medications, and fear of 
harmfulness of medications.  
Adherence was determined 
through self-reporting 
Bissonnette, 
J.M. (2008) 
Nursing Evolutionary Method 
 
Antecedents/Consequences/Related 
Concepts: A prescribed medication 
regimen is the primary antecedent. 
Consequences fall into 3 categories 
– patient related, health care 
professional related and health care 
system related.  Related concepts 
are therapeutic alliance, acceptance 
and agreement. 
Papers identified = 114: 
Nursing – 27 
Psychology – 39 
Medicine – 33 
Pharmacy – 15 
 
Final sample: 
Pharmacy – 8 
Psychology – 15 
Medicine – 15 
Nursing - 15 
Findings by healthcare 
discipline: Nursing uses 
compliance and adherence. 
Psychology uses compliance and 
adherence interchangeably and 
considers these a key component 
of care.  Medicine uses 
adherence and compliance 
synonymously. Pharmacy 
mirrors the approach of 
medicine. 
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Authors/ 
Year/ 
Country 
Discipline Methods Sample/Setting Findings 
Choudhry, N. K., 
Avorn, J., 
Antman, E. M., 
Schneeweiss, S., 
& Shrank, W. H. 
(2007) 
Medicine A Markov Model was created by 
the authors to evaluate cost and 
quality-adjusted life expectancy to 
post MI Medicare patients without 
any out of pocket costs.  This was 
compared with current Medicare 
part D coverage. 
 
No actual patients were 
involved in this study.  It 
was a predictive study. 
Results predicted that Medicare 
patients that were under the 
partial coverage plan would live 
an average of 8.21 QALY and 
incur costs of $114,000.  Cost 
savings was attributed to 
decreased rehospitalizations and 
decreased non-drug 
expenditures. 
Doshi, J. A., 
Zhu, J., Lee, B. 
Y., Kimmel, S. 
E., & Volpp, K. 
G. (2009) 
Medicine Quasiexperimental study utilizing 
administrative data and electronic 
medical record information to 
compare changes in lipid lowering 
medication use over time for 
veterans who experienced increases 
in prescription copayments vs. 
veterans who did not. 
5,604 patients receiving care 
at the Philadelphia VAMC 
and filled at least one rx for 
lipid lowering agent within a 
24 month period prior to 
increase in copayments. 
Increase in co-payments 
adversely affects adherence to 
lipid lowering agents among 
veterans.  This was true even 
among veterans that were at high 
risk for coronary artery disease. 
Fernandez, R., 
Davidson, P., 
Griffiths, R., 
Juergens, C., & 
Salamonson, Y. 
(2007) 
Nursing Cross-sectional study utilizing a 
self-administered questionnaire 
that was mailed to participants.  
Subjects were followed up to 12-24 
months following PCI. 
270 subjects who underwent 
PCI between April 2003 and 
March 2004 and met 
inclusion criteria. 
The authors found that patients 
report high rates of adherence to 
medication after PCI. Patients 
considered themselves to be 
adherent despite missing 
medication dosages. 
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Authors/ 
Year/ 
Country 
Discipline Methods Sample/Setting Findings 
Jackevicius, C. 
A., Li, P., & Tu, 
J. V. (2008) 
Medicine Up to 125 charts from 104 
hospitals in Ontario were 
abstracted.  Charts were identified 
through the EFFECT Registry.  
The Registry was linked to 
prescription claims, demographics, 
physician service and hospital 
discharge.  Non-Ontario residents 
were excluded because the 
investigators did not have access to 
their prescription filling 
information.  Patients admitted to 
long-term care facilities were 
excluded. 
4,591 post MI patients with 
12,832 discharge 
prescriptions written 
Of discharge Rx, 92.3% were for 
cardiac medications.  59.5% had 
< 10 prescriptions filled within 
the 120 days.  Only 74% of 
patients filled all of their 
prescriptions within 120 days.  
Aspirin was not considered a 
prescription and data regarding 
taking aspirin were not collected.  
10% of patients did not fill any 
prescriptions. 
Julius, R. J., 
Novitsky, M., J., 
& Dubin, W. R. 
(2009) 
Psych 
 
Literature Review Search using key words 
“medication adherence” and 
“compliance” = 2,000 
references 
 
After initial search articles 
were limited regarding 
psychiatric medications and 
specific medication classes. 
Also limited to articles 
involving clinical focus. 
Factors affecting medication 
adherence were broken into four 
areas: patient related, 
psychological, medication-
related and social/environmental. 
 
Interventional strategies: 
psychoeducational, cognitive-
behavioral therapy, and 
motivational interviewing. 
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Authors/ 
Year/ 
Country 
Discipline Methods Sample/Setting Findings 
Lehane, E., & 
McCarthy, G. 
(2009) 
Nursing Literature Review surrounding 
medication adherence. 
A critical synthesis of the 
literature to determine key 
attributes for adherence, 
compliance, and 
concordance. 
 
26 papers were reviewed 
The definition of adherence is 
allocated into 5 categories – 
coincidence of patient behavior 
with professional advice, 
relationship as part of the 
process of care, outcome and 
process targets, taking 
medications as prescribed, and 
other factors influencing 
behavior. 
Molloy, G. J., 
Perkins-Porras, 
L., Strike, P. C., 
& Steptoe, A. 
(2008) 
Psychology Prospective study design with 
follow-up data collected for 12 
months after hospital admission. 
Acute Coronary Syndrome 
(ACS) patients – N = 193 
 
Setting: 4 local London 
hospitals 
The authors found that partner 
stress predicted nonadherence.  
Just under 30% of patients were 
deemed to have poor adherence, 
but the authors felt that this is 
and underestimate because of the 
influence of social desirability 
biases. Patients with large social 
networks were more likely to 
attend rehab.  Partner stress and 
small social networks were 
associated with poorer quality of 
life. 
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Authors/ 
Year/ 
Country 
Discipline Methods Sample/Setting Findings 
Rolley, J.X., 
Davidson, P.M., 
Dennison, C.R., 
Ong, A., Everett, 
B., & 
Salamanson, Y. 
(2008) 
Nursing Integrative Literature Review Search of electronic 
databases – CINAHL, 
Medline, Blackwell 
Synergy, Pubmed, Google 
Scholar using key words 
medication, adherence or 
compliance, self-report, and 
questionnaires/tools/surveys. 
Medication adherence depends 
on a range of physical, social, 
economic and psychological 
considerations.  Methods of 
assessing medication adherence 
require further investigation. 
Schoenthaler, A., 
Ogedegbe, G., & 
Allegrante, J. P. 
(2009) 
Psych 
 
Cross-sectional study using Kenny 
and Baron analytic framework of 
mediation 
167 hypertensive African 
American patients in a 
primary care practice. 
Self-efficacy mediates the 
relationship between depressive 
symptoms and medication 
adherence, with the correlation 
that depressive symptoms lead 
the patient to be nonadherent 
with medications. 
Shay, L.E. 
(2008) 
Nursing Walker and Avant Framework Sample: Literature review 
with evaluation of the 
concept of compliance as an 
antecedent.  Non-adherence 
is also reviewed, along with 
associated concepts to 
include self-efficacy, 
motivation, and environment 
 
Setting: Maintenance of 
Long-Term Weight 
Management 
The author discusses compliance 
as an antecedent to adherence.  
Through literature review, 
identifies compliance as having 
a negative connotation. 
Identifies the importance of 
associated antecedents in 
meeting the concept of 
adherence.  Identifies that more 
research is needed in the area of 
weight loss and adherence. 
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Authors/ 
Year/ 
Country 
Discipline Methods Sample/Setting Findings 
Wu, J., Moser, 
D. K., Lennie, T. 
A., & Burkhart, 
P. V. (2008) 
Nursing Longitudinal Study 135 patients with HF.  
Medication Adherence 
measured using the 
Medication Event 
Monitoring System. 
Percentage of doses taken 
and percentage of days 
appropriate doses taken. 
Adherence rates above 88% 
were more sensitive and specific 
to predicting better event free 
survival (decreased number of 
ED visits with increased 
adherence to prescribed 
medication regimen. 
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Summary 
Adherence is the most commonly used term in healthcare to describe a patient’s 
participation in their healthcare.  Originally, compliance was the term that indicated a patient’s 
participation in their healthcare, but due to the paternalistic tone of the term, healthcare has 
adopted the term adherence.  There are many factors that affect adherence including but not 
limited to socioeconomic status, belief in the healthcare system and provider, depression, self-
efficacy, and partner stress.  Medication adherence has been shown to be imperative in 
decreasing risk of mortality and morbidity, and preventing rehospitalization.  The reviewed 
studies demonstrate that medication adherence (adherence is assumed based on prescription fills 
and refills) is critical to positive outcomes post stent placement. 
Current studies have reviewed medication adherence and its relationship to mortality and 
morbidity for the medications supported through evidence for treatment of MI.  Many studies 
have been conducted to explore the relationship between clopidogrel and stent patency.  No 
studies were found that explored the relationship of medication compliance and insurance status.  
Cost as a factor in medication adherence must be considered and is the premise for this project.
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CHAPTER THREE: METHODS 
Implementation of Project 
As part of a quality improvement initiative, pre-test data were collected for the 15-month 
time period between February 2006 and February 2007 for all patients with STEMI that 
presented to the ED at ORMC.  Readmission data were collected until May 2007 to provide 3-
month readmission statistics after the STEMI. A cost-benefit analysis (CBA) was performed 
using these data and a policy was developed to provide clopidogrel to all patients with STEMI 
that had received a BMS and were uninsured.  
The CBA reviewed admissions and 3-month readmissions of uninsured STEMI patients 
who had been treated with BMS.  During this 15-month period of time 17 uninsured patients 
were admitted with STEMI and treated with BMS.  Of these, 4, or 23.5% were readmitted within 
3 months of initial presentation. A fifth uninsured patient was readmitted during this time frame, 
but was listed as “Medicaid pending” and was therefore excluded from analysis. The cause of 
readmission for this was also repeat STEMI.   The repeat STEMI cost the patient in terms of 
health, and cost the organization in terms of finances.  Neither the initial hospitalizations for the 
17 patients, nor the rehospitalizations for the 4 patients were reimbursed.  The direct cost of 
readmissions was approximately $36,700 or an average of $9,175 per patient. 
The cost of providing clopidogrel for future uninsured STEMI patients was calculated by 
projecting a 15% increase in number of uninsured STEMI’s presenting to the ER for the next 
year.  The projected cost of providing the additional 21-days of clopidogrel (Social Work 
Department was already providing 7-days of clopidogrel) to the projected 20 patients was 
calculated to be $720.   
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Assuming a 23% readmission rate for the projected STEMI patients if no clopidogrel is 
provided, a 50% reduction in readmissions (2.5 less readmissions) with clopidogrel provision 
would save the organization about $22,937. 
Based on the results of the CBA, a policy was developed to provide 28-days of 
clopidogrel to uninsured STEMI patients who are treated with BMS.  This policy has slowly 
been adapted to include uninsured STEMI patients who are treated with DES, and any STEMI 
patient who does not have prescription insurance. 
Design 
The design for this study was a retrospective chart review in a pre and post-test type 
format.  The phenomenon being studied is readmission post-stent placement for STEMI with 
subacute thrombosis to the initial stented artery.  This is not a case-control design, but is to study 
project outcomes (Polit & Beck, 2008).  
The major strength of this study design was that all patients were included.  One 
limitation of the study was that discharge education may vary by provider and since data will be 
reviewed retrospectively with no exclusion criteria patient understanding of the importance of 
taking clopidogrel post stent placement was unknown.  Another limitation was that patients with 
prescription insurance were not reviewed for compliance. An assumption was made that these 
patients were filling their prescriptions.  This was considered a limitation because the amount of 
a patient’s co-pay may have been too high for the patient to afford and still prevented the patients 
from acquiring the needed medication.  There is new literature that demonstrates that some 
patients are non-responders to clopidogrel.  The testing that can identify these patients was not  
being used at this organization, therefore this was another limitation of this study. 
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Variables 
The independent variable (IV) was the method provision of 28 days of clopidogrel prior 
to discharge or provision of prescription prior to discharge with the expectation that the patient 
will fill the prescription.  Level of measurement for these variables was nominal.  Demographic 
data included gender (nominal), insurance status (nominal), type of insurance (nominal), patient 
age (ratio/scale), and type of stent (nominal). 
The dependent variable (DV) was rehospitalization for AMI resultant of subacute 
thrombosis in the previously stented culprit vessel.  This variable was also nominal level data. 
Setting/Subjects/Sampling 
This project was conducted at a tertiary care center in Central Florida.  Subjects for the 
pre-test data collection were all patients with STEMI that presented to the center’s ED from 
February 2006, prior to the implementation of the clopidogrel provision policy, until February 
2007, and for the three months following or until May 2007.  Subjects for post-test data 
collection were all patients with STEMI that presented to the center’s ED from February 2009, 
the time the clopidogrel provision policy was initiated, until February 2010, and for the three 
months following or until May 2010. No patients were excluded from the data collection process, 
although the focus was on patients who are uninsured and therefore have a more difficult time 
obtaining prescriptions (an assumption of the project).  An exclusion criteria for the project was 
insurance.  If patients had insurance, they did not receive medication at discharge, only a 
prescription. 
Based on preliminary assessment, it was estimated that 200 subjects or records will meet 
inclusion criteria for the two periods.  Computing chi-square statistics, this sample size will 
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detect an effect size of .20, alpha of .05, at a power of .80.  A sample size of 220 was requested 
from the IRB to ensure that data from all eligible subjects during the two time periods was 
retrieved for analysis. 
Patient charts are coded after discharge by the Coding and Billing Department at the 
Center.  Coding identifies all patients that had an STEMI.  The Quality Department reviews all 
patient charts for those patients who had STEMI to determine whether or not the core measures 
were met.  Quality is able to query all medical record (MR) numbers for patients with STEMI 
during a specified period of time.  Since MR numbers are unique to each patient, they can also be 
used to access readmission information.  MR numbers provided access to charts.  Physician 
documentation and cardiac catheterization results were reviewed, as well as discharge 
instructions. 
Human Subjects 
The benefits of clopidogrel post-stenting are well documented throughout the research, 
and the ACC/AHA recommendation are that all patients receiving coronary stents should take 
clopidogrel for time periods determined by the type of stent they received (Faxon, 2007). Since 
all patients treated with stents for STEMI receive a prescription for clopidogrel at discharge, 
there was minimal risk to the patient in this project. The difference in treatment for subjects 
included in the study was that these patients received actual medication rather than a 
prescription. 
Approval was requested from the Institutional Review Boards (IRB) at the University of 
Central Florida (UCF) and at the Center (Appendix B). The potential risk to the subjects was the 
possibility of a breach of confidentiality.  Health Insurance Portability and Accountability Act 
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(HIPAA) guidelines were followed to prevent a breach of confidentiality.  Each chart reviewed 
was assigned a unique identification number that did not have any association with the medical 
record number.  The log with these numbers was kept by the primary researcher in a locked file 
cabinet.  At the completion of the study, this information was destroyed by shredding.  This 
information was not shared or reused by anyone except as required by law or the IRB’s. 
A waiver of consent was requested and a HIPAA Waiver Authorization Form was 
submitted to the IRB’s.  Additionally, the HIPAA De-identification form was also be submitted. 
Instruments/Data Collection Tool 
An Excel spreadsheet was used to collect data (Appendix B).  This tool was constructed 
for the purposes of this study. Data included gender, age, insurance, type of stent, vessel stented, 
whether or not the patient was readmitted, if readmitted for AMI which vessel was the cause, 
clopidogrel prescription or medication provided, and physician documentation of non-adherence.  
Sovera, a system which houses all patient permanent records for Center was used to obtain the 
data.  Patients were identified by the Quality Department at the Center. 
The current policy to provide clopidogrel to all uninsured STEMI patients who receive 
stents will continue.  The data from the first time period was compared to the time period of 15 
months after the clopidogrel provision policy began. 
In addition to other documentation (physician documentation and cardiac catheterization 
results) reviewed, the Social Work note was included in the second data set to determine if 
eligible patients received their 28-days of clopidogrel prior to discharge.  Excel was chosen for 
the ease of export to SPSS. Direct export also decreased the chance of transcription errors. 
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Procedures 
Medication adherence was evaluated based on 3-month readmission rates and physician 
documentation.   The conceptual definition for adherence is taken from Jackevicius, et al who 
defined adherence as filling and refilling prescriptions. (Jackevicius, Li, & Tu, 2008) 
Prescription fills and refills were not measured in this project because the patients of primary 
interest were those without insurance and there was no way to track fills and refills.   
This project involved data collection prior to implementation of the clopidogrel provision 
policy (Appendix A) and for the time period of fifteen months (so that readmissions may be 
tracked for 3 months after stent placement) after implementation of the policy.  Readmissions for 
the 3 months after stent placement for STEMI were reviewed.   
All charts for patients admitted with STEMI were reviewed.  Data collected included age, 
gender, insurance status, vessel stented, type of stent placed, and if patient was readmitted. 
Readmitted patient charts were reviewed to determine if the readmission was as a result of an 
AMI caused by subacute thrombosis.  Physician documentation was reviewed for documentation 
of clopidogrel non-adherence and Social Work documentation was reviewed to ensure that 
clopidogrel was provided to patient prior to previous discharge.  These results were compared to 
the data collected for the 15 month time period prior to implementation of the clopidogrel 
provision policy. 
Once all data were collected, data were imported into the SPSS 16.0 statistical package 
(Chicago, IL) for data analysis. 
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Data Collection Tool 
In addition to other documentation (physician documentation and cardiac catheterization 
results) reviewed, the Social Work note was included in the second data set to determine if 
eligible patients received their 28-days of clopidogrel prior to discharge.  Excel was chosen for 
the ease of export to SPSS. Direct export  also decreased the chance of transcription errors.  The 
data collection tool used was developed to be specific to this study and to capture the required 
variables, therefore there was no reliability or validity data for this tool. (Appendix B) 
Data Analysis 
Since all data with the exception of age are nominal, non-parametric tests were conducted 
(Munro, 2005).  For this project, chi-square/crosstabs analysis will be done.  Another reason for 
choosing non-parametric tests was because the assumption of normal distribution is not required 
for these tests.  The assumptions of independent categories, levels of measurement, and 
theoretical reasons for categories were made (Munro, 2005). The data to be collected was 
predetermined.  Chi-square/crosstabs was used to compare readmissions by those insured versus 
those uninsured.  It was also used to compare readmissions prior to implementation of the 
clopidogrel provision policy with readmissions occurring after the policy was in place.  
Readmissions were also compared by age group and insurance status, as well as gender and 
insurance status.  
The primary research questions and data analyses were as follows: 
1. Is there a difference in readmission rates between uninsured STEMI patients who 
receive medication, actual “drug-in-hand”, and those who receive a prescription to 
fill? – chi square/crosstabs analysis 
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2. Are uninsured patients who receive “drug-in-hand” less likely to be readmitted than 
insured patients who receive a prescription to fill? – chi square/crosstabs analysis 
 
The a priori alpha level testing for the research questions is .05. 
Limitations 
A major limitation of this project was the inability to identify patients readmitted outside 
of this hospital system. Another limitation of the study was that discharge education may vary by 
provider. Since data was reviewed retrospectively with no exclusion criteria, patient 
understanding of the importance of taking clopidogrel post-stent placement may not have been 
consistent. 
Summary 
The goal of this project was to determine the effectiveness of providing clopidogrel to 
STEMI patients treated with stents in decreasing readmissions with repeat AMI.  AMIs result in 
cardiac compromise and increased mortality and morbidity in patients with cardiac disease.  If 
readmissions can be reduced, the financial impact will be examined.  This data will be presented 
to the Department of Cardiology, Interventional Cardiology Collaborative Practice Team and 
Administration to determine if the policy to provide clopidogrel is beneficial and should be 
continued. 
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CHAPTER FOUR: RESULTS 
Study results are discussed in this chapter. Data are organized by demographics followed 
by the research questions.  Additional findings are also summarized. 
Demographics 
Demographics and statistical results of the retrospective chart review are discussed in this 
chapter.  Statistical analyses were performed using the SPSS 16.0 statistical computer program.  
Data were analyzed using Chi square cross tabulation and T-test for independent samples. The 
study sample for the pre-test group for this project included all patients presenting with STEMI 
from February 2006 to February 2007, and for the 3 months following to assess for readmission.  
The post-test group included all patients presenting with STEMI from February 2008 to February 
2009, and for the 3 months following to assess for readmission.  
Two hundred and one patients (n=201) were eligible for inclusion. One patient in the 
post-test group was excluded because the medical record number could not be found in either of 
the electronic medical records.  A total of 200 charts were reviewed; 100 from the pre-test group 
and 101 from the post test group. A summary of demographic characteristics is provided in Table 
3.  Demographic characteristics of age, gender and insurance status were not statistically 
different between groups.  The mean age for the control group was 59.1 (+ 13.8) and the mean 
age for the post-intervention group was 58.9 (+ 13.6). 
Although no significant differences were noted in the vessel stented between groups, a 
significant difference in type of stent placed was noted.  In the pre-test group, 19% of patients 
admitted with STEMI were treated with (bare metal stents) BMS.  In the post test group, 61.4% 
were treated with BMS (p < .001).   
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Table 3: Demographics 
 
 
Variable 
Group 
Before 
Clopidogrel 
(Control) 
After 
Clopidogrel 
(Intervention) 
All p-value 
N (%) N (%) N (%)  
Gender    .558 
     Male 74 (74.0%) 71 (70.3%) 145 (72.1%)  
     Female 26 (46.4%) 30 (53.6%) 56 (27.9%)  
Insurance Status    .343 
     Uninsured 21 (21.0%) 20 (19.8%) 41 (20.4%)  
     Medicare/ 
     Medicaid 
30 (30.0%) 37 (36.6%) 67 (33.3%)  
     Commercial 39 (39.0%) 40 (39.6%) 79 (39.3%)  
     Medicare + 
     Commercial 
10 (10.0%) 4 (4.0%) 14 (7.0%)  
Type of Stent    < .001 
     Bare Metal 19 (21.3%) 62 (67.4%) 81 (44.8%)  
 
 
Variable 
Group 
Before 
Clopidogrel 
(Control) 
After 
Clopidogrel 
(Intervention) 
All p-value 
N (%) N (%) N (%)  
Type of stent     
     Drug-eluting 70 (78.7%) 30 (32.6%) 100 (55.2%)  
Vessel Stented    .414 
     LAD 39 (43.8%) 35 (37.6%) 74 (40.7%)  
     RCA 34 (38.2%) 44 (47.3%) 78 (42.9%)  
     Cx 10 (11.2%) 7 (7.5%) 17 (9.3%)  
     PDA 0 (0.0%) 2 (2.2%) 2 (1.1%)  
     OM1 1 (1.1%) 3 (3.2%) 4 (2.2%)  
     OM2 1 (1.1%) 0 (0.0%) 1 (0.5%)  
     SVG 3 (3.4%) 2 (2.2%) 5 (2.7%)  
     LIMA 1 (1.1%) 0 (0.0%) 1 (0.5%)  
Legend vessel: LAD – left anterior descending, RCA – right coronary artery, Cx – circumflex, PDA – posterior 
descending artery (a branch of the RCA), OM1 – obtuse marginal 1, OM2 – obtuse marginal 2, SVG – saphenous 
vein graft, LIMA – left internal mammary artery 
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Readmissions 
The first objective of this project was to examine readmission rates in uninsured patients 
who experienced and were treated for STEMI, to determine if those who receive medication in 
hand were less likely to be readmitted than those who simply received a prescription.   
The number of readmissions was not statistically different between groups (n = 5, 23.8% 
control and n = 2, 9.1% intervention)  However, the number of patients admitted with STEMI 
was more than double during the control period versus the intervention. The goal of this project 
was to reduce STEMI readmissions, particularly in the uninsured population.  Five uninsured 
patients (23.8% of readmissions) in the control group were readmitted with STEMI. In the post 
intervention group 2 uninsured patients (9.1% of readmissions) were admitted with STEMI.  
This was not statistically significant (p = .191) most likely due to the small sample size (N = 43).  
Additionally, all readmissions for STEMI patients in the control group occurred within 30 days 
while both readmissions in the post intervention group occurred within 31-60 days.  This was a 
statistically significant finding (p = .008).  Findings are summarized in Table 4. 
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Table 4: Readmission of Patients (n = 43) 
 
 
Readmit 
Group 
Before  
Clopidogrel 
(Control) 
After  
Clopidogrel 
(Intervention) 
All p-value 
N (%) N (%) N (%)  
Cause    .191 
   STEMI 5 (23.8%) 2 (9.1%) 7 (16.3%)  
   Other 16 (76.2%) 20 (90.9%) 36 (83.7%)  
Time to Readmission    .008 
     < 30 days 5 (100.0%) 0 (0.0%) 5 (71.4%)  
     31-60 days 0 (0.0%) 2 (100.0%) 2 (28.6%)  
Legend: STEMI – ST-elevation myocardial infarction 
 
The second objective of this project was to determine if patients that received drug in 
hand were less likely to be readmitted with STEMI than patients who received a prescription.  
All STEMI readmissions from both groups were uninsured patients (N = 7).  There were no 
STEMI readmissions in insured patients during the study time frame. 
Additional Findings 
STEMI readmissions were analyzed by adherence to prescribed medication regimen, 
specific to clopidogrel because readmission as a result of subacute thrombus formation occurs 
with non-adherence to prescribed antiplatelet agents. Uninsured patients in the pre-test group 
were provided with a prescription for clopidogrel. Uninsured patients in the post-test group were 
to be provided with clopidogrel rather than a prescription.  Therefore, adherence to clopidogrel 
and provision of clopidogrel in the post-test group (n = 13) and were analyzed using cross tabs 
Chi-square. All patients (n = 7) that were readmitted with STEMI had physician documentation 
of clopidogrel non-adherence.  Thirteen (13) patients met criteria for clopidogrel provision. Of 
these, 8 patients (61.5%) received clopidogrel and 5 (38.5%) did not.  This was a clinically 
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significant but not statistically significant finding.  Reasons for not getting the clopidogrel 
included being transferred to a telemetry unit other than the existing post interventional unit, 
leaving against medical advice and having an existing prescription for clopidogrel with 
documented medication adherence. 
 
Table 5:  Medication Adherence by MD Documentation 
 
 
Variable 
Group 
Before 
Clopidogrel 
(Control) 
After 
Clopidogrel 
(Intervention) 
All p-value 
N (%) N (%) N (%)  
Adherent     
     No 5 (100.0%) 2 (100.0%) 7 (100%)  
     Yes 0 (0.0%) 0 (0.0%) 0 (0.0%)  
Clopidogrel 
Provided 
    
     Yes N/A 8 (61.5%) 8 (61.5%)  
     No N/A 5 (38.5%) 5 (38.5%)  
 
Findings were presented in this chapter.  The last chapter discusses interpretation of 
findings. 
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CHAPTER FIVE: CONCLUSION 
This chapter discusses findings, limitations, conclusions and implications for nursing 
practice of the study as related to the study questions.  Recommendations for future research 
related to the outcomes of this study are also discussed. 
Discussion 
The main objective of this study was to evaluate outcomes of providing clopidogrel to 
uninsured patients presenting with STEMI who were treated with intervention utilizing BMS or 
DES.  The first research question posed to evaluate these outcomes was “Is there a difference in 
readmission rates between uninsured STEMI patients who receive medication, actual ‘drug-in- 
hand’, and those who receive a prescription to fill?”  To answer this question, readmission rates 
were compared between STEMI patients before and after implementation of a program that 
provided clopidogrel to uninsured patients. 
All-cause readmission rates were similar between groups with 21.9% of STEMI patients 
being readmitted in the pre-test group and 23.0% being readmitted in the post-test group (p = 
0.85). However, a reduction in readmission rates due to subacute thrombus formation leading to 
STEMI was noted between groups, with 5 uninsured patients being readmitted in the pre-test 
group and only 2 uninsured patients in the post-test group. However, this was not a statistically 
significant finding (p = 0.191), most likely related to the small sample size (n = 43). The finding 
is clinically significant (23.8% of readmissions in the pre-test group vs. 9.1% in the post-test 
group).   
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“Subacute thrombus” is the term to describe stent thrombosis which occurs in the first 30 
days after stent implantation. (Grines et al., 2007) By providing the first 30-days worth of 
clopidogrel to uninsured patients, the liklihood of adherence was increased by removing barriers 
to obtain medication and therefore may be related to the decrease in readmissions as a result of 
subacute thrombus formation.  This finding is supported by Rolley, et al (2008) who found that 
medication adherence depends on many factors, including social and economic considerations.  
By providing uninsured patients with medication economic status was taken into consideration 
and removed as a barrier.  Additionally, increased education to STEMI patients regarding the 
importance of taking their clopidogrel as prescribed may have increased adherence, at least in the 
first month after discharge.  A limitation is that factors related to adherence were not directly 
assessed. 
In addition to a reduction in readmission rates, length of time to STEMI readmission was 
evaluated.  In the pre-test group, all STEMI readmissions occurred within 30 days of discharge.  
In the post-test group, STEMI readmissions did not occur within the first 30 days, but in days 31-
60.  This was a both a statistical (p = .008) and clinically significant finding.  Patients in the post-
test group who were treated with BMS and met criteria were provided with 28-days of 
clopidogrel at the time of discharge therefore the patients would have completed their course of 
clopidogrel by the time of their readmission. This finding is supported by Ho, et al (2008) who 
found an increase in adverse events in the first 90 days after discontinuation of clopidogrel in 
patients who had been treated with PCI (Ho et al., 2008), since the two readmissions in the 
intervention group occurred within 31 to 60 days which began the time period after completing 
their 30-day course of clopidogrel. 
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The second research question was “Are uninsured patients who receive ‘drug-in-hand’ 
less likely to be readmitted with repeat STEMI than insured patients who receive a prescription 
to fill?”  To answer this question readmissions were compared by insurance status and by reason 
for readmission.  Both patients who were readmitted with STEMI were uninsured.  Insured 
patients were readmitted for other reasons to include elective surgery, elective staged PCI, 
congestive heart failure, etc.  It should be noted that more uninsured than insured patients were 
readmitted with STEMI from both groups.  This was a statistically significant finding (p = .012).  
This may be due to the lower cost of clopidogrel for patients with insurance, thereby allowing 
them to continue clopidogrel for a longer period as recommended by the guidelines.  It is ideal 
for patients treated with BMS to take clopidogrel for at least 6 months after stent implantation 
(Antman et al., 2008)and uninsured patients may not be able to afford clopidogrel after the first 
month’s supply. 
Patients who met criteria for clopidogrel provision were evaluated to determine if all 
eligible patients received the medication. It was found that only 8 of 13 (61.5%) received 
medication. Five (38.5%) patients did not receive their medication at discharge.  This was not a 
statistically significant finding, but is clearly clinically significant as five patients who were 
supposed to receive the clopidogrel per protocol to did not receive their medication.  Upon 
analysis, this finding can be attributed to patient location (unit) at time of discharge.  The tertiary 
center where this study was conducted has a designated unit for post-PCI patients, both elective 
and those treated for STEMI.  Some STEMI patients are admitted to the Coronary Care Unit 
(CCU) immediately following their intervention and then transferred to a telemetry unit.  Bed 
availability occasionally causes these patients to be transferred to monitored units other than the 
designated post-PCI unit.  Of the patients that did not receive their clopidogrel, one was already 
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taking it, one left against medical advice and the other three were discharged from telemetry 
units other than the post-intervention unit.  Therefore, they did not receive the same evaluation 
by Social Work as those patients on the post-intervention unit.  Additional systems/procedures 
are needed to ensure that all eligible patients receive the medication as indicated. 
Answering the second question assumes that patients who receive medication will be 
adherent.  Therefore, every STEMI readmission was evaluated for adherence to medication 
based on physician documentation.  All STEMI readmissions, both pre-test and post-test, had 
physician documentation of non-adherence to clopidogrel. 
Additional Findings 
The intervention to provide 28 days of clopidogrel to uninsured STEMI patients (patients 
received 2 days of clopidogrel while hospitalized) was based on the ACC/AHA guidelines which 
recommend a minimum of 30 days of clopidogrel to prevent subacute thrombus formation with 
BMS.(Antman et al., 2008)  At the time of project implementation interventional cardiologists 
involved with the Code STEMI process were educated to the criteria for clopidogrel provision 
and to consult Social Work for any patients that met the criteria.   
It is believed that as a result of this project and related physician education (all 
interventional cardiologists taking STEMI call were individually educated by the principal 
investigator), a change in practices for treatment of STEMI occurred.  Prior to the intervention, 
19 (21.3%) of patients were treated with a BMS. After the intervention, 62 (76.5%) patients were 
treated with a BMS, (p = < .001).  This practice change occurred despite insurance status. The 
STEMI process in place at the Center allows 25 minutes from time of presentation to the ED to 
transfer to cardiac catheterization laboratory. This time constraint and the urgency of the 
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situation decreases the opportunity to accurately assess for ability to be adherent.  It was not 
sufficient to identify whether or not a patient had insurance, as insurance co-pays and limitations 
with Medicare prescription coverage can lead to barriers with adherence. Since the ACC/AHA 
guidelines for clopidogrel therapy with BMS recommend a minimum of 30 days, (Antman et al., 
2008) socioeconomic barriers to adherence (Rolley et al., 2008) were decreased for insured 
patients treated with a BMS with this change in practice.  It’s important to note that while the 
ACC/AHA guidelines for clopidogrel therapy with a BMS recommend a minimum of 30 days, 
the guidelines also state it would be ideal if clopidogrel therapy could be continued for up to 12 
months.  While the socioeconomic barriers to obtaining the initial 28-days of clopidogrel were 
decreased, these barriers were not removed and patients were not able to continue the 
recommended ideal therapy. 
Limitations 
The major limitation of this study was the inability to identify patients that may have 
been readmitted with STEMI to a hospital not within the study site’s healthcare system.  Another 
limitation of the study is the small sample size, particularly in the evaluation of STEMI 
readmissions.   
Lack of utilization of the dedicated unit for post-PCI patients was another limitation. This 
resulted in some patients that met criteria for clopidogrel provision not receiving their 
medication.  This may have contributed to the two STEMI readmissions.  However, is also 
identified the need to modify procedures to ensure that all eligible patients receive the 
medication.  Additionally, the nursing staff and nurse practitioner on the dedicated unit provided 
uniform education on the importance of medication adherence, specific to clopidogrel, to all 
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patients.  Patients admitted to other units may or may not have received the same education, 
resulting in varying understanding of the importance of medication adherence. 
Implications for Nursing Practice 
This study evaluated a process improvement project implemented to reduce readmissions 
as a result of subacute thrombus formation in STEMI patients by meeting the ACC/AHA 
guidelines (Antman et al., 2008) for anti-platelet regimens in patients being treated with stents 
for STEMI.  This project was a collaborative effort between the coordinating nurse practitioner, 
interventional cardiologists, Social Work Department, outpatient pharmacy and nursing staff, 
with each department having a specific role.  The goal of the project was to improve medication 
adherence in the uninsured STEMI population by providing clopidogrel “drug-in-hand” and 
thereby eliminate barriers to obtaining the medication.  However, patient evaluation for type of 
stent and education regarding the importance of adherence to clopidogrel were imperative to the 
success of the program.  These points could not have been addressed without collaboration from 
all departments.  As a result of this project, the outpatient pharmacy has added a pharmacy tech 
to deliver the medications to the bedside, eliminating the need for the Social Worker to travel to 
the pharmacy to obtain the medication. 
The education regarding medication adherence provided by the nursing staff was 
consistent for all PCI patients on the designated unit.  Nursing was also instrumental in 
identifying patients that met criteria for clopidogrel provision when a Social Work consult had 
not been entered.  The study also made the nurses more aware of the socioeconomic needs of 
patients. 
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For the purposes of this project, the coordinating nurse practitioner also collaborated with 
Sanofi-Aventis and Bristol Myers Squibb, the pharmaceutical agencies that co-market 
clopidogrel.  As part of their marketing program, both companies provide vouchers for 14 free 
days of clopidogrel for patients receiving new prescriptions for the medication.  Through this 
collaboration, the acute care hospital in Central Florida received more of these vouchers than any 
other site in the country.  The redemption rate for these vouchers, as tracked by these companies, 
is higher in the Central Florida area than in any other area in the country (approximately 80% 
redemption versus approximately 14%). These vouchers were used in conjunction with the 
Social Work department’s resources to provide medication for these patients.  Since the 
completion of this project the policy has been revised to provide 30 days of clopidogrel to any 
patient presenting to the Emergency Department at the facility who is treated with a BMS, and 
has no insurance, no prescription coverage, or whose Medicare prescription benefits have 
expired. 
Resources exist that would allow this policy to be adapted in other facilities.  Multi-
disciplinary collaboration that is physician and advanced practice nurse led is integral to 
implementing this type of project.  Increased utilization of electronic medical records requires 
that information technology be included in the planning stages to assist in identifying these 
patients prior to discharge. 
Recommendations for Further Research 
One of the issues that was identified with this study was providing medication to all 
uninsured STEMI patients that met criteria.  This occurred due to patients being transferred to 
telemetry units other than the designated post-PCI unit.  A prospective study that identified 
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patients at time of STEMI admission and enrolled them would allow for a more controlled study 
and ensure that all eligible patients receive medication prior to discharge. 
Prescription co-pays and restrictions with Medicare coverage have proven to be barriers 
in obtaining medication.  The program should be expanded to evaluate the socioeconomic needs 
of any STEMI patient regardless of insurance status to determine if the patient can reasonably 
afford his/her medication, providing medication to those whose socioeconomic status creates a 
barrier to acquiring clopidogrel. Further research could then be conducted to determine if 
supplying the initial month of clopidogrel improves adherence and decreases readmissions. 
Since the inception of this study a new anti-platelet agent, prasugrel, has been approved 
for use.  Future studies might compare readmission rates between patients prescribed clopidogrel 
versus those prescribed prasugrel.  Consistent education and identification of patients would be 
necessary for both groups. 
Conclusions 
This study evaluated the benefit of providing clopidogrel to uninsured STEMI patients 
who were treated with a BMS.  The pre-test group showed a 23.8% readmission rate with 
uninsured STEMI patients.  The post-test group showed a 9.1% readmission rate.  The cost of 
providing the clopidogrel to the 8 patients that received it was $297.92, compared to average 
direct cost of one STEMI readmission which was $9,175.00, demonstrating a cost savings just 
under $27,000.00.  The medication in addition to the focused education each patient received 
may have contributed to this reduction in readmissions. 
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Additionally, a transition to increased use of BMS (21.3% vs. 67.4%) in STEMI patients 
was noted in the post-test group.  This was most likely a result of increased physician awareness 
of barriers to adherence. 
This program should be continued with increased focus on ensuring that patients are 
placed on the appropriate unit.  Additionally, other vulnerable populations should be considered 
for inclusion in the program.  
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APPENDIX A: PLAVIX PROVISION FOR INDIGENT CODE STEMI STENT 
RECIPIENTS 
 44 
 There are three criteria a patient must meet in order to qualify for 28 days of Plavix. The 
patient must be a Code STEMI, uninsured and the recipient of a stent. The stent can be either 
Bare Metal (BMS) or Drug Eluting (DES). In addition, a patient will qualify if they have 
insurance without prescription coverage. They must still be a Code STEMI and the recipient of a 
stent. 
The process is as follows: 
1) Social Work/Case Management Tech identifies the Code STEMI patients who have 
received a stent and is self pay status or without prescription coverage. 
2) Two scripts are needed, both for 14 days. The ARNP may be able to assist with 
writing the scripts if the doctor is not available. 
3) SW/CMT must complete the Walgreens referral process for fourteen days of Plavix 
then take the referral, a fourteen day trial card and the two scripts to OHScripts to be 
processed. The trial card can be obtained from ARNP Sita Price on 5B/Cang or 
Carolyn La Londe. SW/CMT later delivers the medication to the patient at bedside. 
4) The unit pharmacist needs to be informed that one of these patients has been 
identified so that they can provide a bottle of aspirin. A copy of the script will need to 
be provided to the pharmacist. 
5) SW/CMT should also provide the patient with a patient assistance program packet 
which can be obtained through the Needymeds website. 
6) If an uninsured patient is going to be on Plavix for any length of time this is a good 
indication that an OCMC referral would be appropriate. 
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7) **Weekends/Holidays: The patient will have to take the Walgreens referral, 14 day 
trial card and scripts to Walgreens for processing. A 14 day trial card will be kept in 
Team Leader’s (Dari) mailbox. 
 
If you should have any questions about the process please contact: 
 
Sita Price, ARNP 321-841-5168 
Carolyn La Londe, MSW 321-841-5168 or 407-980-6037 
 46 
APPENDIX B: DATA COLLECTION TOOL 
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Variables Codes 
ID               
Age               
Gender 1 = Male 2 = Female           
Insurance 1 = Uninsured 2 = Medicare/ 
Medicaid 
3 = Commercial 
Insurance 
4 = Medicare + 
Commercial 
5 = Not 
Available 
    
Type of Intervention 0 = N/A 1 = Stent 2 = PCI/No Stent 3 = CABG     
Vessel_Stent 1 = LAD 2 = RCA 3 = Circ 4 = OM1 5 = OM2 6 = PDA 7 = SVG 8 = LIMA 
Type_Stent 1 = BMS 2 = DES 3 = Not Available         
Readmit_STEMI 0 = No 1 = Yes 2 = Not Available         
Cause of Readmission 0 = N/A 1 = STEMI/MI 2 = Other      
Time to Readmit 0 = N/A 1 = Within 30 
Days 
2 = Within 90 days 3 = Not Available       
Thrombus 0 = No 1 = Yes 2 = Not Available         
MD Documentation of 
Non-adherence 
0 = No 1 = Yes 3 = Not 
Documented 
        
Plavix Provided 0 = No 1 = Yes 2 = N/A (insured) 3 = Not 
Documented 
      
Adherence, if 
Readmitted 
0 = No 1 = Yes 2 = N/A 3 = Not Available       
LOS if Readmitted # of Days 0 = N/A       
Discharge Disposition 1 = Home 2 = SNF 3 = ALF 4 = Expired 5 = Not 
Available 
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APPENDIX C: UCF IRB 
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APPENDIX D: ORMC IRB 
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